WEKO3
アイテム
Nivolumab for the treatment of malignant melanoma in a patient with pre-existing myasthenia gravis
https://doi.org/10.18999/nagjms.78.1.119
https://doi.org/10.18999/nagjms.78.1.119a998717f-b9ed-4661-9498-be572300b705
| 名前 / ファイル | ライセンス | アクション |
|---|---|---|
31_Maeda.pdf (322.9 kB)
|
|
| Item type | 紀要論文 / Departmental Bulletin Paper(1) | |||||
|---|---|---|---|---|---|---|
| 公開日 | 2016-02-23 | |||||
| タイトル | ||||||
| タイトル | Nivolumab for the treatment of malignant melanoma in a patient with pre-existing myasthenia gravis | |||||
| 言語 | en | |||||
| 著者 |
Maeda, Osamu
× Maeda, Osamu× Yokota, Kenji× Atsuta, Naoki× Katsuno, Masahisa× Akiyama, Masashi× Ando, Yuichi |
|||||
| アクセス権 | ||||||
| アクセス権 | open access | |||||
| アクセス権URI | http://purl.org/coar/access_right/c_abf2 | |||||
| キーワード | ||||||
| 主題Scheme | Other | |||||
| 主題 | malignant melanoma | |||||
| キーワード | ||||||
| 主題Scheme | Other | |||||
| 主題 | nivolumab | |||||
| キーワード | ||||||
| 主題Scheme | Other | |||||
| 主題 | anti-programmed death 1 (PD-1) monoclonal antibody | |||||
| キーワード | ||||||
| 主題Scheme | Other | |||||
| 主題 | myasthenia gravis | |||||
| キーワード | ||||||
| 主題Scheme | Other | |||||
| 主題 | creatine phosphokinase | |||||
| 抄録 | ||||||
| 内容記述タイプ | Abstract | |||||
| 内容記述 | A 79-year-old man with lymph node recurrence of malignant melanoma received nivolumab, an antiprogrammed death 1 (PD-1) monoclonal antibody. He had pre-existing ocular myasthenia gravis (MG) and a continued small amount of corticosteroid. Grade 3 creatine phosphokinase elevation appeared after two doses of nivolumab, and the treatment was postponed until it improved to grade 1. After three doses of nivolumab, he experienced diplopia and facial muscle weakness which were consistent with an acute exacerbation of MG, and the symptoms relieved without additional treatment for MG. He achieved shrinkage of metastasis after ten doses of nivolumab. Although a case who died due to MG after administration of nivolumab was reported recently, pre-existing MG is considered not to be always a contraindication of nivolumab. | |||||
| 言語 | en | |||||
| 出版者 | ||||||
| 出版者 | Nagoya University Graduate School of Medicine, School of Medicine | |||||
| 言語 | en | |||||
| 言語 | ||||||
| 言語 | eng | |||||
| 資源タイプ | ||||||
| 資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
| 資源タイプ | departmental bulletin paper | |||||
| 出版タイプ | ||||||
| 出版タイプ | VoR | |||||
| 出版タイプResource | http://purl.org/coar/version/c_970fb48d4fbd8a85 | |||||
| ID登録 | ||||||
| ID登録 | 10.18999/nagjms.78.1.119 | |||||
| ID登録タイプ | JaLC | |||||
| 関連情報 | ||||||
| 関連タイプ | isVersionOf | |||||
| 識別子タイプ | URI | |||||
| 関連識別子 | http://www.med.nagoya-u.ac.jp/medlib/nagoya_j_med_sci/781.html | |||||
| ISSN（print） | ||||||
| 収録物識別子タイプ | PISSN | |||||
| 収録物識別子 | 0027-7622 | |||||
| ISSN（Online） | ||||||
| 収録物識別子タイプ | EISSN | |||||
| 収録物識別子 | 2186-3326 | |||||
| 書誌情報 |
en : Nagoya Journal of Medical Science 巻 78, 号 1, p. 119-122, 発行日 2016-02 |
|||||
| 著者版フラグ | ||||||
| 値 | publisher | |||||
| URI | ||||||
| 識別子 | http://hdl.handle.net/2237/23541 | |||||
| 識別子タイプ | HDL | |||||
